Below are links to all our assay results deposited in PubChem BioAssay.
Click the AID numbers to find the structures of all compounds tested, complete assay protocols, and results.

Results discussed in Shadrick, et al. (2013) Discovering New Medicines Targeting Helicases: Challenges and Recent Progress. J. Biomol. Screen 18, 761-781

• AID: 1800. Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3) [Primary Screening]

• AID: 1800. Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3) [Primary Screening]

• AID: 1830 . Summary of probe development efforts to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3).

• AID: 1845. Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID)

• AID: 1943. Fluorescence-based confirmation biochemical high throughput screening assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3)

• AID: 1945. Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID) in triplicate.

• AID: 2172. Counterscreen for HCV NS3 helicase inhibitors: Fluorescence-based biochemical high-throughput dose response assay for compounds that cause fluorescent intercalator displacement (FID).

• AID: 2173. Fluorescence-based biochemical high throughput dose response assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3).

• AID: 2476. Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence-based biochemical dose response assay for compounds that cause fluorescent intercalator displacement (FID)

• AID: 2474. Late stage results for the probe development effort to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence-based biochemical dose response assay for inhibitors of NS3.

Results discussed in Li, et al. (2012) Optimization of Potent Hepatitis C Virus NS3 Helicase Inhibitors Isolated from the Yellow Dyes Thioflavine S and Primuline. J. Med. Chem. 55, 3319-3330

• AID: 463231. Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): luminescence-based cell-based dose response assay to determine whether compounds that inhibit replication of HCV RNA replicon are cytotoxic.

• AID: 463235. Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): luminescence-based cell-based dose response assay to determine whether compounds inhibit replication of HCV RNA replicon.

• AID: 485301. Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): real-time florescence-based biochemical assay to determine whether compounds inhibit the helicase encoded by one or more HCV strains.

• AID: 504419. Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): real-time florescence-based biochemical assay to determine whether compounds inhibit the helicase encoded by one or more HCV strains: Set 2

• AID: 588360. Late-stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): luminescence-based cell-based dose response assay to determine whether compounds that inhibit replication of HCV RNA replicon are cytotoxic.

• AID: 602275. Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): real-time florescence-based biochemical assay to determine whether compounds inhibit the helicase encoded by one or more HCV strains: Set 3.

• AID: 623972 . Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): florescence-based biochemical assay with EtBr to determine whether compounds bind DNA.

• AID: 623970. Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): florescence-based biochemical assay with SYBR to determine whether compounds bind DNA.

Results discussed in Sweeney et al. (2013) Primuline Derivatives That Mimic RNA To Stimulate Hepatitis C Virus NS3 Helicase-Catalyzed ATP Hydrolysis. J. Biol. Chem., 288, 19949-19957.

• AID: 623973. Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): absorbance-based biochemical assay to determine whether compounds inhibit ATPase activity.

Results discussed in Ndjomou et al. Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation. Antiviral Res. 96, 245-255

• AID: 623968. Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): RT-PCR-based cell-based assay to determine the effect of compounds on RNA levels.

• AID: 623964. Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): florescence-based biochemical assay to determine whether compounds inhibit the HCV protease NS3-NS4A.

• AID: 623962 . Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): luminescence-based cell-based assay to determine whether compounds inhibit HCV replication

• AID: 623961. Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): luminescence-based cell-based assay to determine cytotoxicity of compounds.

Results discussed in Mukherjee et al. (2012) Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays.Nucleic Acids Res. 40, 8607-8621

• AID: 687035. Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase.

• AID: 687037. Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex.

• AID: 623966. Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): florescence polarization-based biochemical assay to determine whether compounds can displace the E. coli single stranded DNA binding protein.

Results discussed in Mukherjee et al. (2014). Ebselen Inhibits Hepatitis C Virus NS3 Helicase Binding to Nucleic Acid and Prevents Viral Replication. ACS Chem Biol 9, 2393-2403.

• AID: 687043. Fluorescence polarization based primary biochemical high throughput screening assay of ChemBridge compounds to identify inhibitors of hepatitis C virus non-structural protein 3 helicase.

• AID: 720485. Fluorescence polarization based confirmation biochemical high throughput screening assay of ChemBridge compounds to identify inhibitors of hepatitis C non-structural protein 3 helicase.

• AID: 720486. Biochemical high throughput counterscreening assay of selected ChemBridge compounds for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that inhibit the ability of E. coli ssDNA binding protein to bind DNA.

• AID: 720487. Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of selected ChemBridge compounds: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled oligonucleotide bound to E. coli SSB.

• AID: 720488. Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of a ChemBridge library: biochemical high-throughput screening assay to identify compounds that cause fluorescent interference.

• AID: 720489. Fluorescence-based confirmation counterscreen assay for HCV NS3 helicase inhibitors of a ChemBridge library: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex.

• AID 743264. Fluorescence polarization based biochemical confirmatory assay of ChemBridge compounds to identify inhibitors of hepatitis C non-structural protein 3 helicase

• AID 743268 Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucleotide bound to E. coli SSB

• AID 743270 Fluorescence polarization based primary biochemical high throughput screening assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase

• AID 743271 Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein

• AID 743272 Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference